Abbott Laboratories (ABT) Coverage Initiated at BTIG Research

BTIG Research began coverage on shares of Abbott Laboratories (NYSE:ABT) in a research report released on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $56.00 target price on the healthcare product maker’s stock.

ABT has been the topic of several other reports. Zacks Investment Research cut Abbott Laboratories from a hold rating to a sell rating in a report on Tuesday, March 28th. Royal Bank Of Canada lifted their price objective on Abbott Laboratories from $46.00 to $50.00 and gave the stock an outperform rating in a report on Wednesday, March 1st. Jefferies Group LLC reiterated a buy rating and issued a $52.00 price objective (up from $51.00) on shares of Abbott Laboratories in a report on Saturday, March 11th. BMO Capital Markets cut Abbott Laboratories from an outperform rating to a market perform rating and set a $48.00 price objective on the stock. in a report on Tuesday, March 14th. Finally, TheStreet upgraded Abbott Laboratories from a c+ rating to a b rating in a report on Wednesday, March 8th. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Abbott Laboratories has a consensus rating of Buy and a consensus price target of $50.58.

Abbott Laboratories (NYSE ABT) opened at 48.91 on Wednesday. The company has a market capitalization of $84.87 billion, a price-to-earnings ratio of 50.89 and a beta of 1.08. Abbott Laboratories has a 12 month low of $36.76 and a 12 month high of $49.45. The stock’s 50 day moving average price is $45.37 and its 200 day moving average price is $43.20.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, April 19th. The healthcare product maker reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.05. Abbott Laboratories had a return on equity of 14.91% and a net margin of 6.74%. The company had revenue of $6.34 billion for the quarter, compared to analysts’ expectations of $6.16 billion. During the same period in the previous year, the firm posted $0.41 EPS. Abbott Laboratories’s revenue was up 29.7% compared to the same quarter last year. Equities research analysts anticipate that Abbott Laboratories will post $2.47 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Abbott Laboratories (ABT) Coverage Initiated at BTIG Research” was originally posted by sleekmoney and is the property of of sleekmoney. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://sleekmoney.com/abbott-laboratories-abt-coverage-initiated-at-btig-research/1942203.html.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th will be given a dividend of $0.265 per share. This represents a $1.06 annualized dividend and a dividend yield of 2.17%. The ex-dividend date of this dividend is Wednesday, July 12th. Abbott Laboratories’s payout ratio is presently 110.42%.

In other news, insider Roger Bird sold 5,600 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $43.82, for a total transaction of $245,392.00. Following the sale, the insider now owns 51,313 shares of the company’s stock, valued at approximately $2,248,535.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Stephen R. Fussell sold 196,550 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $46.00, for a total transaction of $9,041,300.00. Following the sale, the insider now directly owns 221,488 shares in the company, valued at approximately $10,188,448. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 206,902 shares of company stock worth $9,497,761. Corporate insiders own 0.76% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Janney Capital Management LLC raised its stake in Abbott Laboratories by 0.4% in the first quarter. Janney Capital Management LLC now owns 6,229 shares of the healthcare product maker’s stock valued at $276,000 after buying an additional 26 shares during the last quarter. Zions Bancorporation raised its stake in Abbott Laboratories by 0.4% in the fourth quarter. Zions Bancorporation now owns 7,824 shares of the healthcare product maker’s stock valued at $301,000 after buying an additional 32 shares during the last quarter. Cedar Hill Associates LLC raised its stake in Abbott Laboratories by 0.3% in the fourth quarter. Cedar Hill Associates LLC now owns 14,261 shares of the healthcare product maker’s stock valued at $548,000 after buying an additional 41 shares during the last quarter. Pure Financial Advisors Inc. raised its stake in Abbott Laboratories by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 11,004 shares of the healthcare product maker’s stock valued at $489,000 after buying an additional 45 shares during the last quarter. Finally, Delta Asset Management LLC TN raised its stake in Abbott Laboratories by 1.3% in the first quarter. Delta Asset Management LLC TN now owns 3,996 shares of the healthcare product maker’s stock valued at $178,000 after buying an additional 51 shares during the last quarter. 71.10% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/abbott-laboratories-abt-coverage-initiated-at-btig-research/1942203.html

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *